Vesugen: A Khavinson Tripeptide Bioregulator (Lys-Glu-Asp)

Research summary. Vesugen is a short tripeptide (Lys-Glu-Asp; KED) developed within the Khavinson "peptide bioregulator" research programme in St. Petersburg, Russia. Within that framework, it is described as a vascular-tropic bioregulator with reported effects on endothelial function, atherosclerotic-process markers, and downstream consequences such as neuroprotection in the central nervous system. As with the wider Khavinson bioregulator family, the supporting literature is concentrated within the originating Russian research programme, and independent Western validation of the underlying mechanistic model is limited. Researchers should treat reported effects as hypothesis-generating.

Molecular profile

• Sequence: Lys-Glu-Asp (KED; H-Lys-Glu-Asp-OH)
• Molecular formula: C₁₅H₂₆N₄O₈
• Molecular weight: ~390.4 g/mol
• PubChem CID: 87571363
• Class: Khavinson short-chain peptide bioregulator (cytomedine family)
• Reported tissue tropism: Vascular endothelium

Mechanism of action

The mechanistic framework proposed within the Khavinson programme for short bioregulators including Vesugen emphasises:

• Direct DNA/chromatin interaction. Khavinson and colleagues have proposed that short peptides interact with promoter regions and modulate transcription of tissue-specific genes.
• Endothelial gene expression. Vesugen has been reported to modulate expression of vascular-relevant genes including endothelin-1 and sirtuin-1 in research-programme reports.
• Sirtuin-1 activation framing. Some reports describe Vesugen-associated changes in SIRT1 expression, with the suggestion of calorie-restriction-mimetic effects.
• Limited independent receptor or signalling characterisation. As with the wider bioregulator class, the standard pharmacology framework (receptor identification, structure–activity relationships, independent in vitro reproductions) is not well established outside the originating programme.

Preclinical and applied research

Endothelial and atherosclerotic markers. Within the Khavinson research programme, Vesugen has been reported to influence endothelial-function markers and to reduce atherosclerotic-process indicators in animal and cell-culture models.

Central nervous system. Reported neuroprotective effects in CNS contexts are described within the same programme, with proposed relevance to memory, synaptic plasticity, and hypoxia tolerance — framed as secondary to vascular effects in the CNS microvasculature.

Sirtuin-1 and calorie-restriction framing. Some reports describe Vesugen as a sirtuin-1 modulator, with associated framing as a calorie-restriction-mimetic intervention. This framing should be evaluated against the broader sirtuin literature and the specific evidence quality of the underlying experiments.

Independent validation. Independent Western preclinical replication of these specific findings is limited.

Current research status

Vesugen is not approved by any major Western regulator (FDA, EMA, MHRA) for any indication. It is supplied as a research-grade peptide where available and is not intended for self-administration. Researchers working with this peptide should approach it as an investigational research material, recognise the limited independent literature, and design experiments with appropriate vehicle controls and orthogonal endpoints.

Key takeaways for researchers

• Vesugen is a Lys-Glu-Asp (KED) tripeptide developed within the Khavinson bioregulator research programme.
• Within that framework, it is described as vascular-tropic with reported effects on endothelin-1 and sirtuin-1 expression and downstream CNS-protective effects.
• Supporting literature is concentrated in the originating Russian research programme; independent Western validation of the underlying mechanistic model is limited.
• It is not FDA-approved and is supplied as a research-grade peptide for laboratory use only.

References

1. Khavinson VK, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2014;156(6):737–743.
2. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.

---

This article is provided for educational and research purposes only. Vesugen is a research peptide. It is not currently FDA-approved and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. The supporting literature is concentrated in a single research programme and independent validation is limited. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.